Nicox names Doug Hubatsch chief scientific adviser, shifting R&D leadership to Siobhan Garbutt

• Nicox shifted Doug Hubatsch from EVP, Head of R&D and Chief Scientific Officer to Chief Scientific Advisor, ending his operational management duties.
• Siobhan Garbutt, Vice President and Head of Clinical Development, will lead the development team; she joined in July 2022.
• Garbutt ran NCX 470 clinical work, played a major role in drafting the NDA, holds nearly 20 years of ophthalmology-focused clinical development experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020130OMX_____CNEWS_FR_GNW1001260500_fr) on September 02, 2026, and is solely responsible for the information contained therein.